Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting


Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA. The SELECT-AML-1 trial is evaluating tamibarotene, Syros' first-in-class selective retinoic acid receptor alpha (RAR?) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.

Details of the poster presentation are as follows:

Presentation Title: Initial Results from SELECT-AML-1, a Phase 2 study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Session Title: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Session Date & Time: Saturday, December 10, 2022, 5:30 ? 7:30 pm CT (6:30 ? 8:30 pm ET)
Location: Ernest N. Morial Convention Center, Hall D
Publication Number: 1444

The abstract is now available online on the ASH Conference website at:
https://www.hematology.org/meetings/annual-meeting.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RAR? agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.


These press releases may also interest you

at 22:37
PickUp USA Fitness (www.pickupusafitness.com), a fast-growing basketball gym franchise headquartered in Los Angeles, CA, announced their newest location would open in February 2023 in Jacksonville, FL. After a year of planning, the new Jacksonville...

at 21:42
BioArctic AB's (publ) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBItm), an investigational anti-amyloid beta (A?)...

at 20:12
ExeGi Pharma LLC, a leader in the development of live biotherapeutic drugs and probiotics, announced today that the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. This clearance allows the...

at 20:01
Glaucoma Research Foundation (GRF) will host the 12th Annual Glaucoma 360 New Horizons Forum on February 3rd at San Francisco's iconic Westin St. Francis Hotel.  ...

at 20:00
Winners of the 36th International ARC Awards have been announcement. The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022...

at 19:21
Multi #1 international best-selling award-winning author, founder and CEO of Speak Up World LLC, (http://www.SpeakUpWomen.com), Jennifer S. Wilkov announces the 2023 April Speak Up Women...



News published on 3 november 2022 at 09:25 and distributed by: